Laumas Sandeep's Insider Trades & SAST Disclosures
Laumas Sandeep's most recent trade in Instil Bio Inc was a trade of 45,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Laumas Sandeep.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Laumas Sandeep | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2024 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Laumas Sandeep | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 415,000 | 415,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 234,000 | 234,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 240,000 | 240,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges